Oral Thyroid hormone In Healthy volunteers Study: an interventional study on the effect of thyroid hormone on coagulation and fibrinolytic parameters.

Oral Thyroid hormone In Healthy volunteers Study: an interventional study on the effect of thyroid hormone on coagulation and fibrinolytic parameters. - OTIHS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON31212

Enrollment

Registered

2007-07-16

Start date

2007-07-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coagulation system excess of thyroid hormone hemostasis hyperthyroidism

Interventions

Levothyroxine 0,3 mg per day for 14 days.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Adult >= 18 years and

Exclusion criteria

Exclusion criteria: - Long term drug therapy including use or oral anticonceptive agents. - Ongoing febrile, inflammatory, cardiovascular, renal, pulmonary, liver, neurological, endocrine, neoplastic diseases.

Design outcomes

Primary

Measure	Time frame
Coagulation and fibrinolytic parameters: 1) Prothrombin fragment 1+2 (F1+2) 2) Von Willebrand factor antigen (vWfAg) 3) D-dimer (ELISA assay) 4) Prothrombin time (PT) 5) Activated partial thromboplastin time (aPTT) 6) von Willebrand factor activity 7) factor VIII:C 8) Plasmin-antiplasmin complex (PAP) 9) Thrombin generation test (ETP)	—

Secondary

Measure	Time frame
Lipid parameters: 1) Total cholesterol 2) Low density lipoprotein (LDL) 3) High density lipoprotein (HDL) 4) Lipoprotein (a) (Lp(a)) 5) Apolipoprotein A-I (Apo A-I) 6) Apolipoprotein B (Apo B) 7) CRP (C-Reactive protein)	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)